The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.

ABSTRACT:

Objective

Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV^-pos DLBCL) is a recently identified entity. Data regarding outcome to frontline immuno-chemotherapy are conflicting. Although the prognostic impact of the tumour microenvironment (TME) in EBV^-neg DLBCL is well-established, it remains untested whether the TME influences survival in EBV^-pos DLBCL. There are no data with new digital gene expression technologies that simultaneously interrogate the virus, B cells and the tumour microenvironment (TME).

Methods

We used the NanoString™ platform in a population-based cohort of 433 patients to establish if the technology could detect EBV in the tumour biopsies and to investigate the influence that EBV has on the complex tumour mic

SUBMITTER: Keane C 

PROVIDER: S-EPMC6899834 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature